In summary, the molecular profiling of pancreatic tumors has unveiled critical insights into the genomic landscape, revealing the prominence of key players such as TP53, CDKN2A, SMAD4 and KRAS. This evidence concerns the gene CDKN2A and pancreatic neoplasm.